Tracers / [18F]AlF-H3RESCA-FAPI
[18F]AlF-H3RESCA-FAPI
Also written as [F-18]AlF-H3RESCA-FAPI
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- FAP-targeted small molecule with H3RESCA chelator (FAPI-based)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 40006089
- Clinical application
- PET imaging of FAP-expressing tumors PMID 40006089
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | custom manifold | SPE | 92.4 ± 2.4% yes | >95% | H3RESCA-FAPI | 40006089 2025 Pharmaceuticals (Basel) 18F− was loaded onto an activated QMA ion exchange column (Waters GmbH, Eschborn, Germany), which had been previously eluted with 1 mL of saline and air-dried. — the decay-corrected RCY was 92.4 ± 2.4% (n = 6) |
Need this precursor?We can point you to suppliers for [18F]AlF-H3RESCA-FAPI, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40006089. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40006089: 'H3RESCA-FAPI (compound 3) was synthesized (Scheme 1)'. Stage set/updated at stage 23 from PMID 40006089: 'PET imaging was performed in U87MG tumor-bearing mice, with a blocking study to assess tracer specificity.'.